DGXQuest Diagnostics Inc.
Quest Diagnostics has a real, but not overwhelming, competitive advantage built on national scale, dense collection logistics, payer relationships, and broad physician access. Its strongest moat pillars are efficient scale and cost advantages, which make it hard for smaller labs to match service breadth and economics in routine outpatient testing. Switching costs exist for payors and providers, but they are only moderate because contracts are periodically rebid and many tests are commoditized. Brand and intellectual-property advantages are helpful but not decisive. Overall, Quest looks like a Narrow Moat with a stable trend: durable enough to resist fragmentation, yet still exposed to reimbursement pressure, hospital insourcing, and price competition.
Sign in to see the full analysis
The Strategic Factor Breakdown, Management Quality Assessment, and AI Impact Assessment are available to registered users — it's free.
DGX’s most notable strength is its reliable cash generation, with free cash flow consistently positive and rebounding to support dividends, buybacks, and ongoing reinvestment. Revenue and earnings weakened from 2021 to 2023 but have since recovered, with TTM momentum improving; however, margin compression shows profitability has not fully regained its former strength. The balance sheet is adequate rather than robust: liquidity has tightened, debt remains elevated, and heavy goodwill leaves tangible equity negative, even as reported equity and retained earnings rise. Forecasts point to steadier growth and manageable leverage, but returns on capital remain below prior highs. Overall, DGX presents a solid, defensive financial profile with moderate growth, fair profitability, and some balance-sheet pressure, consistent with mid-range ratings.
Sign in to see the full analysis
The Income Statement, Balance Sheet, Cash Flow, Key Ratios, Forecast, and Fair Value analysis are available to registered users — it's free.
The most probable next move is a modest recovery attempt toward the $196.85 to $197.94 resistance band, with $199.7 as the next upside checkpoint if momentum improves. If buyers fail to hold $193.33, the stock could retest $192.24 and $191.62, making that zone the key downside risk.
DGX shows a mixed but still constructive technical profile. Short-term momentum has cooled, with price slipping below the 20-day average and MACD turning bearish, yet the stock remains above the 50-day and 200-day lines, keeping the broader trend intact. Medium- and long-term conditions are more favorable because the shares remain in Golden Cross territory and the 52-week structure is still trending upward. The key levels to watch are $193.33 and $191.62 on the downside, with $195.75 to $197.34 acting as the first meaningful resistance cluster before the stock can challenge higher pivots.
Sign in for the full breakdown
See the full short, medium & long-term indicator breakdowns and support/resistance levels — free for registered users.
Disclaimer: The analysis on this page is generated by AI and is provided for informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any security. Always conduct your own due diligence and consult a qualified financial adviser before making any investment decisions.